BUDAPEST, Hungary, May 17 /PRNewswire/ -- Leading French pharmaceutical company Fournier Pharma and ComGenex Inc. have announced a long-term collaboration for the provision of exclusive chemistry services.
"We are pleased that Fournier Pharma has agreed to extend the initial 16-month project into a multi-year collaboration by relying on our proprietary technologies and quality of service provided. Undoubtedly, this represents a significant achievement for ComGenex in a highly competitive market", commented Michael Bossert, ComGenex' Associate Director, Sales & Development. This satisfaction was shared by Dr. Jean-Louis Junien, Fournier Pharma's Chief Scientific Officer: "We had the opportunity to appreciate the value of ComGenex comprehensive chemistry services and we are delighted to continue our collaboration in the future, too", he added.
The full details of this research collaboration have not been fully disclosed but it is established that ComGenex will provide over a 3-year period exclusive chemistry services and will be actually involved in the chemical design of the initial chemical structures, according to Fournier Pharma's indications.
This multi-year agreement underlines ComGenex commitment to providing reliable and long-lasting collaborations for complex drug discovery projects. "The extension of our initial collaboration with Fournier Pharma demonstrates the success of ComGenex chemistry team to address effectively the needs of our drug discovery partners. We are pleased to have the chance to consolidate our business relationship with a dynamic player such as Fournier Pharma", said Dr. Laszlo Urge, CEO of ComGenex.
About Fournier Pharma
Fournier Pharma is a European pharmaceutical company operating worldwide, dedicated to improving health and quality of life through innovative healthcare products for the treatment of metabolic diseases and the prevention of cardiovascular risk. With a 30-year expertise in lipidology, Fournier Pharma benefits from a strong cardiovascular franchise among general practitioners cardiologists and endocrinologists. Therefore, a large part of the activity is based on drugs prescribed for lipid disorders, and notably the fenofibrate, lipid-lowering agent discovered and produced by Fournier Pharma and marketed in more than 80 countries across the world.
With a total of 3,406 employees, Fournier Pharma is directly established in 30 countries today and earns three-quarters of its turnover outside France. Its total sales reached 593 million euros in 2004, a 7% increase compared to 2003.
More information is available at http://www.fournierpharma.com/
About ComGenex Inc:
ComGenex is an integrated discovery service provider for the pharmaceutical and biotechnology industries offering proprietary services and methods in the area of chemistry, protein expression, instrumentation, high-throughput analytics, informatics and ADME. The company has a proven track record of successful collaborations with major pharmaceutical, chemical and biotechnology companies worldwide.